Metabolite-based dietary supplementation in human type 1 diabetes is associated with microbiota and immune modulation
- Author(s)
- Bell, KJ; Saad, S; Tillett, BJ; McGuire, HM; Bordbar, S; Yap, YA; Nguyen, LT; Wilkins, MR; Corley, S; Brodie, S; Duong, S; Wright, CJ; Twigg, S; de St Groth, BF; Harrison, LC; Mackay, CR; Gurzov, EN; Hamilton-Williams, EE; Mariño, E;
- Details
- Publication Year 2022-01-19,Volume 10,Issue #1,Page 9
- Journal Title
- Microbiome
- Abstract
- BACKGROUND: Short-chain fatty acids (SCFAs) produced by the gut microbiota have beneficial anti-inflammatory and gut homeostasis effects and prevent type 1 diabetes (T1D) in mice. Reduced SCFA production indicates a loss of beneficial bacteria, commonly associated with chronic autoimmune and inflammatory diseases, including T1D and type 2 diabetes. Here, we addressed whether a metabolite-based dietary supplement has an impact on humans with T1D. We conducted a single-arm pilot-and-feasibility trial with high-amylose maize-resistant starch modified with acetate and butyrate (HAMSAB) to assess safety, while monitoring changes in the gut microbiota in alignment with modulation of the immune system status. RESULTS: HAMSAB supplement was administered for 6 weeks with follow-up at 12 weeks in adults with long-standing T1D. Increased concentrations of SCFA acetate, propionate, and butyrate in stools and plasma were in concert with a shift in the composition and function of the gut microbiota. While glucose control and insulin requirements did not change, subjects with the highest SCFA concentrations exhibited the best glycemic control. Bifidobacterium longum, Bifidobacterium adolescentis, and vitamin B7 production correlated with lower HbA1c and basal insulin requirements. Circulating B and T cells developed a more regulatory phenotype post-intervention. CONCLUSION: Changes in gut microbiota composition, function, and immune profile following 6 weeks of HAMSAB supplementation were associated with increased SCFAs in stools and plasma. The persistence of these effects suggests that targeting dietary SCFAs may be a mechanism to alter immune profiles, promote immune tolerance, and improve glycemic control for the treatment of T1D. TRIAL REGISTRATION: ACTRN12618001391268. Registered 20 August 2018, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=375792 Video Abstract.
- Publisher
- BMC
- Keywords
- Autoimmunity; Dietary-metabolites; Immune regulation; Microbiota; SCFAs; Type 1 diabetes
- Research Division(s)
- Population Health And Immunity
- PubMed ID
- 35045871
- Publisher's Version
- https://doi.org/10.1186/s40168-021-01193-9
- Open Access at Publisher's Site
https://doi.org/10.1186/s40168-021-01193-9- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2022-02-16 10:16:36
Last Modified: 2022-02-18 03:23:05